Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.31 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.31 |
| ▸ | SPTLC3 | Q9NUV7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787219 | 0.80 | JAK2 (0.41) | JAK2P2RY2SLC5A2 | |
| SCHEMBL21787056 | 0.73 | JAK2 (0.49) | JAK2ADORA1P2RY2SLC5A2 | |
| SCHEMBL21786988 | 0.70 | — | — | |
| SCHEMBL25753580 | 0.68 | POLG (0.44) | P2RY2 | |
| SCHEMBL22327080 | 0.68 | POLG (0.44) | P2RY2 | |
| SCHEMBL22327076 | 0.68 | POLG (0.44) | P2RY2 | |
| SCHEMBL22327216 | 0.68 | POLG (0.44) | P2RY2 | |
| SCHEMBL25753931 | 0.68 | POLG (0.44) | P2RY2 | |
| SCHEMBL23734382 | 0.67 | POLG (0.33) | P2RY2 | |
| SCHEMBL24858810 | 0.65 | POLG (0.43) | P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | JAK2 1849/4885ADORA1 456/4885P2RY2 1781/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | JAK2 2078/4885ADORA1 389/4885P2RY2 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.